Abstract:Both reversible noncovalent inhibitors and irreversible covalent inhibitors targeting tyrosine kinases have their disadvantages. The reversible covalent inhibitors with electrophilic group cyanoacrylamide as warheads reacting with cysteine residues could solve the dilemmas. However, there are still several unresolved issues regarding the electrophilic groups. In this manuscript, a series of EGFR inhibitors with double electron-withdrawing substituents introduced into the C-alpha position on the olefin bond were designed and synthesized. The binding structures and characteristics of inhibitors with the kinase in both the first noncovalent binding phase and the second covalent binding step were explored and combined with molecular docking and molecular dynamics simulations. Then, the reverse beta-elimination reactions of the thiol-Michael adducts were investigated by applying density functional theory calculations. In addition, the effects of different electrophilic substituents of C-alpha on the binding between the inhibitors and kinase were elucidated. The results suggested that the electrophilicity and size of the electron-withdrawing groups play an important role in the specific interactions during the reaction. The compounds with the electron-withdrawing groups that had medium electrostatic and steric complementarity to the kinase active site could cooperatively stabilize the complexes and showed relatively good potent activities in the kinase assay experiment. The mechanical and structural information in this study could enhance our understanding of the functioning of the electron-withdrawing groups in the covalent inhibitors. The results might help to design efficient cysteine targeting inhibitors in the future.

Covalent inhibitors meet epigenetics: New opportunities

Targeting Epigenetic Regulators with Covalent Small-Molecule Inhibitors

Covalent Inhibition in Drug Discovery

Epigenetics-targeted drugs: current paradigms and future challenges

Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Advances in covalent drug discovery

Targeting cancer epigenetic pathways with small-molecule compounds: Therapeutic efficacy and combination therapies

A Perspective on Covalent Inhibitors: Research and Development Trends of Warheads and Targets

Small-Molecule Inhibitors Overcome Epigenetic Reprogramming for Cancer Therapy

Targeting Epigenetic Regulatory Enzymes for Cancer Therapeutics: Novel Small-Molecule Epidrug Development

Recent applications of covalent chemistries in protein-protein interaction inhibitors

The Development of Epigenetics and Related Inhibitors for Targeted Drug Design in Cancer Therapy

Advanced technologies for screening and identifying covalent inhibitors

DNA methyltransferase inhibitors: an updated patent review (2012-2015)

Application of covalent modality in proximity-induced drug pharmacology: Early development, current strategy, and feature directions

Discovery of cysteine-targeting covalent histone methyltransferase inhibitors

Chemical Regulation of Epigenetic Modifications: Opportunities for New Cancer Therapy

Epigenetic therapies targeting histone lysine methylation: complex mechanisms and clinical challenges

Research Progress of Dual Inhibitors Targeting Crosstalk Between Histone Epigenetic Modulators for Cancer Therapy